Cullgen

Co-founder Ying Luo serves as Chief Executive Officer, overseeing corporate strategy and capital allocation, while co-founder Jin Wang serves as Chief Scientific Officer, leading the scientific direction and platform development. Wang’s academic lab at Baylor College of Medicine laid the groundwork for the company’s protein-degradation technology (per public record). Investment decisions are made by the executive team in consultation with the board, which includes representatives from lead investors Sequoia China and LYFE Capital.

uSMITE is a small-molecule degrader platform designed to tag intracellular disease-causing proteins for destruction via the ubiquitin-proteasome system. The company claims an ability to identify degraders against targets that conventional occupancy-based small molecules cannot address (per the firm’s official communications). Unlike some competitors focused on heterobifunctional PROTACs, Cullgen’s approach incorporates proprietary screening technology intended to identify novel E3 ligase binders, potentially expanding the repertoire of targetable proteins.

Cullgen operates both as a discovery platform and as a drug developer. The company has advanced preclinical programs in oncology and inflammatory disease, using its uSMITE platform to nominate clinical candidates. Through its subsidiary Anji Pharma, certain assets are positioned for independent clinical advancement, while the primary Cullgen entity also pursues internal development. The December 2023 reverse-merger agreement with Pulmatrix suggests a near-term push toward public-company clinical-readout timelines (per the firm, December 2023).

Anji Pharma operates as a subsidiary of Cullgen, created to independently advance select clinical-stage programs, particularly those with near-term regulatory pathways. This structure allows the parent company to maintain focus on its preclinical degradation pipeline while enabling Anji Pharma to pursue a separate development and financing strategy. The arrangement is unusual among early-stage protein-degradation biotechs and reflects a modular approach to managing platform risk versus clinical attrition risk.

Cullgen prioritizes oncology as its lead therapeutic area, with additional programs in inflammatory and immune-mediated diseases. The company has not publicly disclosed a full target list, but its Astellas Pharma partnership focuses on immuno-oncology applications of targeted protein degradation. The firm’s public statements indicate an emphasis on historically undruggable intracellular targets, the same class that attracted large pharma interest to the degradation modality broadly.

Cullgen raised a Series A round in its founding year and followed with a Series B in June 2020 co-led by Sequoia China and LYFE Capital (per the firm, June 2020). Total disclosed private funding exceeded $50 million as of early 2021. In December 2023, the company announced a reverse-merger agreement with NASDAQ-listed Pulmatrix, which would provide a public-company listing and access to equity capital markets without a traditional IPO (per the firm, December 2023).

Cullgen competes with larger, US-headquartered protein-degradation companies such as Arvinas and Kymera Therapeutics, both of which are publicly traded and have clinical-stage assets. Cullgen’s differentiation rests on its Asian R&D footprint, its uSMITE platform’s screening approach to novel E3 ligases, and its subsidiary model via Anji Pharma. The firm’s competitive challenge is a narrower resource base relative to well-capitalized peers, making its reverse-merger public listing a consequential step for future head-to-head development timelines.